Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.

Slides:



Advertisements
Similar presentations
UICC HPV and Cervical Cancer Curriculum Table of contents UICC HPV and CERVICAL CANCER CURRICULUM.
Advertisements

Demographic and clinical characteristics associated with timely utilization of cervical cancer prevention services for women enrolled in comprehensive.
HPV.  Many risk factors for development of cervical cancer. no routinely used positive predictive biological markers, which identify women at risk of.
Repositioning Prevention and Control of Cancers of Reproductive Organs in Kenya Repositioning Prevention and Control of Cancers of Reproductive Organs.
Cervical Screening and HPV testing
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Treatment Options for CIN Cervical Cancer screening is designed to detect CIN If CIN is present treatment should theoretically avoid subsequent cancer.
COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.
Cervical Cancer and HPV Z Mike Chirenje MD FRCOG University of Zimbabwe, Department of Obstetrics and Gynecology, Harare, Zimbabwe.
ACCP Evidence base: Implications for policy and practice R. Sankaranarayanan MD Head, Screening Group World Health Organization (WHO) International Agency.
M. Munjoma. Outline Burden of HPV Disease HPV in Zimbabwe HPV Lab Development HPV Protocols.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
HPV and cervical screening Test of cure
Screening for Cervical Cancer
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.
Benign and premalignant disease of the cervix
Cervical Cancer and HIV: Interactions and Interventions Jean R. Anderson, M.D. Jhpiego, an affiliate of Johns Hopkins University The Johns Hopkins University.
Anticipated impact on HPV infection from HPV vaccination programs – cause for optimism Dr Paddy Horner.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
 Human papillomaviruses are a group of more than 100 viruses  They are called papillomaviruses because certain types may cause papillomas (or warts),
Immunotherapy with Leukocyte Interleukin, Injection for Human Papilloma Virus (HPV) Induced Cervical Dysplasia In HIV Patients Taylor G 1,2, Ely L 1, Wolff.
 Cervical cancer is a malignant tumour deriving from cells of the "cervix uteri", which is the lower part of uterus.  Begins in the lining of the cervix.
wrong to say cervical erosion -this condition appear at ( puberty ) ( pregnancy )
Case Presentations: Pre-Invasive Cervical Neoplasia
Cervical Cancer Screening
Bayesian Modelling for Clinical Decision Support: Cervical Cancer Screening1/31 University of Pittsburgh Medical Center (UPMC) Magee-Womens Hospital (MWH)
CERVICAL SCREENING WITH LUVIVA MACHINE FOR EARLY DETECTION OF CERVICAL DYSPLASIA: EXPERIENCE FROM EKITI STATE, NIGERIA Sunday O. Omoya, Abimbola M. Obimakinde.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Is Cervical Cancer Screening a necessary part of HIV care in Zimbabwe? ZIMA Congress Friday 29 th August.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
HPV VACCINATION Dr Frida Mghamba 2 nd East Africa WE CAN Summit 11 th September 2014.
Cervical Intraepithelial Neoplasm
Adult Medical-Surgical Nursing
TEMPLATE DESIGN © Outcome of Large Loop Excision of Transformation Zone (LLETZ ) in women over forty at two London Hospitals.
Integration of HIV/AIDS and Cervical Cancer Programs for Improved Health Outcomes in Tanzania Dr. January Zilabumba IMA World Health 30 November, 2015.
Premalignant lesions of the cervix. Applied anatomy.
Mary Rose Giattas Marya Plotkin Giulia Besana Maryjane Lacoste Safina Yuma Robert Kamala Mainza Lukobo-Durrell Megan Wysong Harris Sharon Kibwana Kelly.
Cervical Cancer How We Can Prevent It Dr Quek Swee Chong Himalayan Women’s Health Project 30 August 2014.
HPV-related anogenital cancers
Sexually Transmitted Disease Viruses: HPV, Herpes, and HIV By: Jennifer Pena University of Houston— Downtown.
CERVICAL CANCER PREVENTION STRATEGIES Z Mike Chirenje MD FRCOG Department of Obstetrics and Gynaecology University of Zimbabwe, Harare Zimbabwe
HIV & HPV Co-infections: Clinical Presentation & Management
#AIDS2016 Cervical Cancer Prevention in Africa: The Future Nelly Yatich, DrPH University of California San Francisco July 19 th, 2016.
Cervical cancer screening and treatment among HIV+ women in Cambodia: feasible and high yielding M.-E. Raguenaud 1, P. Isaakidis 1, S.A. Khim 1, C. Ping.
NHS Cervical Screening Programme Introducing HPV Triage
University of Rajarata.
INTRODUCTION: CERVICAL CANCER SCREENING
Treatment Options for Cervical Cancer in Low Income Countries
Department of Gynaecology and Obstetrics
Cervical Cancer Colposcopy & Treatment
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
School of Life and Health Sciences, University of Ulster Jordanstown
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
Obstetrician and Gynecologist Malawi Inaugural Cancer Symposium
Hoa Nguyen Lam, Huyen Suong Ho Thi et al.
Nasreen Abdullah, MD, MPH
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
Dorcas Obori-Yeboah and team
Nat. Rev. Clin. Oncol. doi: /nrclinonc
SBÜ KAYSERİ ERH Doç. Dr. Gökhan Açmaz
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Screening to Prevent Invasive Cervical Cancer (Resource-Stratified)
SH-sheikhhasani Gyn-oncologist
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA
Trial profile. *Four women received discordant vaccines (one woman was enrolled twice and received 3 doses of each vaccine and three women received 2 doses.
Oregon HPV Summit - June 2019 Nasreen Abdullah, MD, MPH
Presentation transcript:

Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202

Presentation Outline Background Objectives Methodology Results Conclusion and recommendations

Background Cervical carcinoma the most common malignancy in Zimbabwean women, is preventable Women living with HIV (WLWHIV) have higher prevalence of Human Papillomavirus (HPV) infection, & multiple subtypes including oncogenic HPV They are at risk of higher grade lesions, higher rates of recurrent & persistent cervical disease & invasive cervical cancer (ICC) Primary prevention with HPV vaccination is possible Secondary prevention includes screening & treatment of early lesions

Objectives This study was done in order to: Describe the prevalence of cervical disease in a cohort of women receiving care for HIV infection Provide evidence to support the need for cervical cancer screening for WLWHIV in Zimbabwe

Methodology Newlands Clinic provides comprehensive care & treatment for 5500 patients (60% female) Cervical cancer screening using visual inspection with acetic acid (VIA) method introduced for sexually active females VIA & appropriate treatment with either cryotherapy or loop electrosurgical excision procedure (LEEP) A record review of women undergoing initial cervical screening from Jan 2011 to Dec 2014 Assessment of women with VIA+ve lesions at initial screening (IS) & histological analysis of 326 biopsies was done

Results Percentage of Women with VIA Positive Lesions at IS Year 34.9% (314/899) % (439/1357) % (126/406) % (110/333)2014 The mean was 32.8 %

Histological Diagnosis Histological diagnosis of 326 biopsy specimens obtained during LEEP CIN I % CIN II % CIN III % ICC - 2%

Conclusions & Recommendations Cervical disease (defined by VIA+ve) was present in 1/3 of women at initial screening Histology of 326 biopsy specimens showed moderate to severe dysplasia (CIN II & III) in 59.4% & ICC in 2% These data illustrate the high prevalence of cervical disease & support the need for cervical cancer screening as a mandatory component of care for all WLWHIV The urgency for HPV vaccination as primary prevention strategy is highlighted

Thank you for your attention